CSPC Innovation(SZ:300765) 智通财经网·2026-01-15 09:33Core Viewpoint - The company, XinNuoWei (300765.SZ), forecasts a net loss attributable to shareholders of 170 million to 255 million yuan for the year 2025, marking a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotechnology, has increased the company's ownership to 80%, which will amplify the impact of Jushi's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, the company made significant advancements in its innovation pipeline, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - A monoclonal antibody product, Omabuzumab for new indications, has been approved for market launch, while another monoclonal antibody product, Pertuzumab injection, has had its market application accepted [1] - Two ADC products have entered the Phase III clinical stage, reflecting the company's commitment to advancing its research and development efforts [1] Group 3: Functional Raw Materials Business - The company has worked to strengthen its position in the functional raw materials sector, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products have slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]